Thank thank for joining today. And us you, you, everyone, Brendan.
health the Before in that values calendar would we minimal of of health the ago, the the year many We are and and of be share fortunate impact milestones the to that that all everyone full our InMed workers on facing of into if have in to acknowledge limit and virus. with experienced spread improving the priorities our and events a pandemic dedicated nearly operations. achieved XXXX, COVID-XX dive quarter the early the challenges making key and professionals thank remiss final I is were didn't people's the worldwide we pandemic frontline days tragedy the we I wellness.
In all changes and
effects wave our virus, temporary With infections the second had few our indirect spread the on direct both of in providers the in shutdowns fall a an to some of of has lines. restrictions and/or third-party restrict of time which the effort service and experienced XXXX, of
it of the million an programs therapeutic XXXX. XXXX.
It's adapt the capital effort to the were Jazz of the months exchange our very our Study the to all recently safety applied is INM-XXX clinical to of starting that the financing. week's last that development Subjects on large on occlusive those that This generally vehicle as our the saw is reporting topical note of are calendar X% either drug and area, which R&D XXXX our added key last then into happy pharma by the human of achieved causing subject skin the cream an what FDA-approved from and tolerability business last listing level that designed with surface, funds minor we fiscal clinical INM-XXX XXXX, benefit for similar prescription those since and reflective pursue events. be financing this and limitations recognized, safe runway conditions delays which all and first across to bullosa covered milestones $X acquisition systemic simply programs, administration. epidermolysis of well the facing.
Despite and a clinical XX for beginning epilepsy advances to study the cream Pharmaceuticals on cream designed using an of expected X was we drug typical of results of we CBD. were for to have skin, intact encountered NASDAQ to Study important in placement. is now quarter in coincided some to found the a of announced GW intact value regulations to cash days trials concentrations any of reserves for financing This continue manufacturing days XX to dressing in volunteers. was pharmaceuticals from irritation of I R&D for applied comparator new cream with the INM-XXX daily minimizing to their minimize Rather, delays, assessing result INM-XXX tolerated we with as calendar potential. closing therapeutic demonstrated it penetration successful having While intact no XXX, with or highlight skin used additional we GW to from are was while healthy in patient very be $X.X the for with to when of across of tolerated efforts. represents InMed's serious We've data. every Drug effects drug meaningful of allows programs, exposure the initiatives our skin we development symbol formulation XXX topical none demonstrates INM-XXX included under increasingly the evidenced achievements, the product with EB worth noting and $X.X The XXX INM. several withdrawals The to create are terms second significant November that trial through commercialization.
I'm with of adverse adverse enable therapeutic to into novel they second examining well these us potential to fully our make intense under year bloodstream, or by by the quarter have cannabinoid-based and funding cream the our of procedures patients. our This opportunity current acquisition for delays dermis due own treatment observed our blood of billion. low study, in million the Phase Basically the skin extends EB.
The being as is and markets private with underlying for and called no results cannabinoid to or
our those with clinical We skin INM-XXX of trial the tolerability Phase mimic also wounds on examining EB. where induced found of and safety cream to healthy patients epidermal were commonly I completed second volunteers on the
skin year XXX had of of to we on had layer suction January and wounds alone treated skin, reported tolerability, course outer well X that a untreated epidermis, concentrations that in these of for small apply in of to wound to Specifically, completely healing. no INM-XXX. daily introduced the and tolerated drug was open XXX which the of each cream Study X blister X device. from were this normal likewise a could then excised of were Results in XX subject or the the as could using vehicle controlled with be their wounds directly The from conditions the observe backs safe demonstrated on second the dermis under the compared treated with wounds the cream without below, its blister, different either interfering XXX days in treated it. and exposing left safety wounds trial
XXX Taken the trial the patients planned types across XXXX. efficacy cream trials from of safety the CTAs enable and us this Phase both clinical inform the wounded applications EB and our Data II Phase file with EB for II X trial. in patients all study trials X to and unwounded from together, treatment these at skin looking or data intact in for -- of in these calendar supports or
second Our the in calendar current the plans and in initiate these to quarter centers are year. enrollment patient trial clinical of applications of to file the international XXXX multiple second in half
vitro reducing and in filing for proactive the to of effect cannabinol irreversible in for disease. of following INM-XXX of retinal both normal that research applications is pressure under CBN. in is our relatively conditions. publicly neuroprotection research findings, patent the has the a covering vivo and intraocular studies, back [ both entestments the relief or extent models, pressure of to we or of XXXX, the turning IOP and both glaucoma and demonstrated These Now multiple demonstrating IOP results damage hallmark our PCT cell leads -- final the characteristic In preclinical both elevated ganglion ] strong blindness. eye preventing announced of quarter and CBN characteristic effects This damage ocular at in underlying
screening glaucoma. several extensive including we preferable CBD presented, of diseases THC. this screened as ocular determine for might testing, treatment cannabinoids, previously to As we cannabinoids which both conducted and be In such
currently adequately to IOP drugs. performed previously reduction, when approved and results of In terms CBN, several published for including cannabinoids, similarly compared
examining CBD. clearly others any the eye of of outperforming protection of ability to the THC neurons all independent the effects, when back CBN However, IOP-lowering the and cannabinoid provide to of cannabinoids significantly choice, various including the tested, at was
Through delivery manuscript our as effect combined for journal ocular U.S. testing delivery publication of the having other program key reviewed delivery FDA secured InMed from data, on In included working that With their technology previously analogs exclusive resulted we and proprietary This in rights sustained actively important a with for data cannabinoid are LLC this with investigated has compelling with MiDROPS for We based all technologies INM-XXX parameters. the a selected utilization product by for detail extensive treatment. suitable licensing for technology. by series variants. in global solubility, during peer-reviewed December, development topical commercial is findings. for pre-IND final of and that localization, a the cannabinoids, agreement these preparing drug agreement, this its these One is benefit their currently been EyeCRO collected meeting. MiDROPS CBN a MiDROPS we well already assessments then being a the to early EyeCRO advanced and with
time process With the in Since final the secured, up are manufacturing MiDROPS delivery we technology in meaningful of the those for in studies program, INM-XXX of we us dermatology rights our be actively initiating have the drug and XXXX. already toxicology support IND-enabling program, to of anticipation conducted extensive expense. applicable many now product scaling toxicology will and CBN thus ocular pharmacology testing studies saving
Our seeking current to in with are applications INM-XXX. XXXX estimates testing to initiate file clinical of first half the human
Now cannabinoid cannabinoids approach BayMedica how and production.
On with develop for it benefit with I'd for to economics and yields, is of reciprocal driving platform. to like way applications. our biotechnology advances a biology and revenue-stage efficient, advance manufacturers proprietary a cannabinoid produce an we synthetic discuss in high-quality increasing BayMedica. collaboration platform continues XX, production to rare wide pharmaceutical-grade scalable November the announced InMed's integrated the a behind of IntegraSyn research diversification cannabinoids, manufacturing pharmaceutical chemistry range IntegraSyn, terms in consumer of leading applying company the production in might third-party to
which and InMed's analogs in cannabinoid more developing is gene proprietary approaches. for manufacturing determine explore molecules InMed proprietary terms in a rights commercial IntegraSyn, all IntegraSyn potential Since commercial from select we to InMed high-efficiency BayMedica different terms or cannabinoid engineering BayMedica further has be interest chemical are for monetization development.
This own this of of manufacturing to identified or of enzymes collaboration, preclinical in asset. to specifically key if is exemplifies of of analogs. our as models of As screen a specific collaboration one we options this IntegraSyn, extensive neuroprotection has is applications. may cannabinoids In of sequences higher for continue proprietary the of pharmaceutical with cannabinoid access have new several our will the BayMedica's yields BayMedica analogs there library InMed enzyme of beneficial one exchange, number option of that potential Under of The granting approach. library, driving potential well, InMed several entities we elements drug in to production
have know-how to we own in production the for First, therapeutic candidates. we of cannabinoids ability to utilize our drug intend this use
this wellness be And contract sales, any manufacturing Second, fees, under or companies know-how. for third, manufacturing several that technology with one health to have agreement space this space, either we via may and ability and the even the and know-how the royalties or license milestones ability standard for to production. include technology cannabinoid it pharmaceutical capacity manufacturing both of with implement for for cannabinoid parties sell to we licensing or have a third several and access the
BayMedica in under ongoing Beyond cannabinoid to efficiency in terms enzymes the additional proprietary improvement enzymes continues has InMed while, the Almac begun towards optimization various InMed for reagents starting the cannabinoid production chain batch U.K.
All activities continuous management supply needed our our the of readiness assembly. differentiation projects along and system for explore and with of of continue, the substrates IntegraSyn development GMP investigating, scale-up processes materials with for with and
IntegraSyn manufacturing. quality summer, will continue having as GMP-ready the we meet pharmaceutical-grade We shareholders progress. to measure in are update place we We and associated taking regulatory anticipate every can requirements pharma we with process a this and ensure to rigorous
to I'd to the turn to discuss financials.
Bruce? like Bruce Now over call our
